In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Radius Health Inc. (NASDAQ:RDUS) reported that Farallon Capital has picked up 803,800 of common stock as of 2017-05-18.
The acquisition brings the aggregate amount owned by Farallon Capital to a total of 803,800 representing less than 1.9% stake in the company.
For those not familiar with the company, Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, abaloparatide for subcutaneous injection, or abaloparatide-SC, has completed Phase III development for potential use in the treatment of women with postmenopausal osteoporosis. Its clinical pipeline also includes an investigational abaloparatide transdermal patch, or abaloparatide-TD, for potential use in the treatment of women with postmenopausal osteoporosis. In addition, the Company is evaluating its investigational product candidate, RAD1901, a selective estrogen receptor down-regulator/degrader (SERD) for potential use in the treatment of hormone-driven and/or hormone-resistant breast cancer, as well as for potential use in the treatment of vasomotor symptoms in postmenopausal women.
A glance at Radius Health Inc. (NASDAQ:RDUS)’s key stats reveals a current market capitalization of 1.36 Billion based on 43.38 Million shares outstanding and a price at last close of $32.81 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-05-12, Biotech picked up 15,000 at a purchase price of $34.00. This brings their total holding to 4,873,799 as of the date of the filing.
On the sell side, the most recent transaction saw Ward unload 25,000 shares at a sale price of $62.77. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Radius Health Inc. (NASDAQ:RDUS) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.